Syntax Bio Teams Up with Mayo Clinic to Advance Diabetes Treatment
CHICAGO, June 10, 2026 Syntax Bio announced a research and development collaboration with Mayo Clinic to accelerate the development...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CHICAGO, June 10, 2026 Syntax Bio announced a research and development collaboration with Mayo Clinic to accelerate the development...
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
MIAMI, Florida, United States – May 10, 2026 Longeveron announced details from a constructive Type C meeting with the...
IRVING, Texas, May 5, 2026 Caris Life Sciences has announced the launch of Caris MI Clarityâ„¢, an advanced AI-powered...
SAN DIEGO, May 6, 2026 Gallant, an emerging animal health biotechnology company focused on regenerative veterinary medicine, has announced...
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Seoul, South Korea, December 19, 2025 — MEDIPOST Co., Ltd., a fully integrated cell therapy biotechnology company, has entered...
DUBLIN, IRELAND & LONDON, UK — December 8, 2025 — Ayrmid Ltd., parent company of Gamida Cell Inc., announced...
CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding,...
